Home > Publications Database > Proteomic Profiling of CSF Reveals Inflammatory Pathways Associated with Tau Neuropathology in Alzheimer's Disease > print

001     283155
005     20260129104040.0
024 7 _ |a 10.1002/alz70856_106780
|2 doi
024 7 _ |a pmid:41505027
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00051
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kinton, Sofia
|b 0
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Proteomic Profiling of CSF Reveals Inflammatory Pathways Associated with Tau Neuropathology in Alzheimer's Disease
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1769593693_29847
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Aggregation of amyloid beta (Aβ) and tau proteins is a hallmark of Alzheimer's disease (AD) and tauopathies. In AD, extracellular deposition of Aβ peptide precedes tau aggregation and the onset of neuroinflammatory processes. Both neuroinflammation and tau deposition are associated with synaptic loss, neurodegeneration, and cognitive decline. However, the precise sequence of events from amyloid deposition to tau aggregation, neuroinflammation, and neurodegeneration remains unclear. A cross-sectional analysis of tau and other proteins in the cerebrospinal fluid (CSF) of AD patients can provide insight into the inflammatory and degenerative processes. Tau levels may be used as a proxy for disease progression, and we hypothesize that the expression of neuroinflammatory markers will be modulated in response to increasing tau aggregation.To investigate this, we collaborated with the EPND-biomarker consortium to analyze over 150 human CSF samples from AD and control patients. We measured levels of Aβ1-40, Aβ1-42, pTau181, and total tau, and conducted proteomic profiling using the O-link and SomaScan platforms. Next, AD patients were stratified into Aβ+Tau+ and Aβ+Tau- groups to identify biomarkers associated with Aβ and/or tau aggregation.As expected, inflammation markers were elevated in AD CSF samples compared to controls. Interestingly, we observed distinct correlations between these markers and amyloid versus tau pathology biomarkers. Approximately 10% of the measured CSF proteins (∼250 proteins) showed significant differences (p < 0.05) between AD and control samples. CSF samples with elevated tau levels exhibited altered levels of proteins involved in the complement cascade, cytokine-cytokine receptor interactions, cell adhesion, and vesicular transport.Increased inflammation markers were observed in AD. Proteins linked to innate immune response and synaptic loss were significantly altered in relation to tau aggregation. These findings are crucial for guiding therapeutic strategies for neurodegenerative diseases and assessing their efficacy.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Proteomics
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
700 1 _ |a Dujardin, Simon
|b 1
700 1 _ |a Levit, Mikhail
|b 2
700 1 _ |a Pao, Ping-Chieh
|b 3
700 1 _ |a Sardi, Pablo
|b 4
700 1 _ |a Zhang, Bailin
|b 5
700 1 _ |a Dodge, James
|b 6
700 1 _ |a Krishnan, Rajaraman
|b 7
700 1 _ |a Rizzo, Marianna
|b 8
700 1 _ |a Teunissen, Charlotte E
|b 9
700 1 _ |a Zetterberg, Henrik
|b 10
700 1 _ |a Blennow, Kaj
|b 11
700 1 _ |a Kollmorgen, Gwendlyn
|b 12
700 1 _ |a Ramia, Nancy
|b 13
700 1 _ |a Fernandes, Sara B Gomes
|b 14
700 1 _ |a Krüger, Rejko
|b 15
700 1 _ |a Borejko, Olga
|b 16
700 1 _ |a Aarsland, Dag
|b 17
700 1 _ |a Hu, Michele
|b 18
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 19
|u dzne
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 20
|u dzne
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 21
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 22
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 23
|u dzne
700 1 _ |a van der Flier, Wiesje M
|b 24
700 1 _ |a Lemstra, Afina W
|b 25
700 1 _ |a Tijms, Betty M
|b 26
700 1 _ |a Frisoni, Giovanni B
|b 27
700 1 _ |a Hort, Jakub
|b 28
700 1 _ |a Nedelska, Zuzana
|b 29
700 1 _ |a Chevalier, Claire
|b 30
700 1 _ |a Visser, Pieter Jelle
|b 31
700 1 _ |a Vos, Stephanie J B
|b 32
773 _ _ |a 10.1002/alz70856_106780
|g Vol. 21 Suppl 2, no. S2, p. e106780
|0 PERI:(DE-600)2201940-6
|n S2
|p e106780
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283155/files/DZNE-2026-00051.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283155/files/DZNE-2026-00051.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283155
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2811916
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2320009
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2000032
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)2811324
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 0
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 1
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 2
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1011102
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21